BlossomHill Therapeutics, Inc.
BLSM
NASDAQ16.10
USD
-0.28
- -
CIK
0001839970
ISIN
US0951301003
CUSIP
095130100
Return %
Stock
S&P500
1Y
0.63
19.43
3Y
0.63
76.01
5Y
0.63
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jing Rong Jean Cui
- Full Time Employees
- 63
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10255 Science Center Drive, Suite 200 San Diego CA United States of America 92121
- IPO Date
- Aug 7, 2026
- CIK
- 0001839970
- Website
- bhtherapeutics.com
- Similar Companies
- Business
- BlossomHill Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics for oncology and autoimmune diseases. The company focuses on innovative biologics and small-mue modalities targeting validated and novel pathways with potential disease-modifying effects. Primary business activity centers on research and development, clinical trial execution, regulatory submission support, and collaboration-driven manufacturing and service offerings. Headquartered in Wilmington, Delaware, BlossomHill operates research and development facilities in the United States and Europe, with additional manufacturing and pilot-scale operations in North America and Asia. Founding year is 2020. Main products and services: biologics and small-mue therapeutic candidates across preclinical and clinical stages; drug discovery and target validation services; translational science, biomarker development, and companion diagnostic support; formulation development, GMP manufacturing scalability; regulatory affairs consulting and strategic advisory services; clinical trial design, protocol development, and management; partnering and licensing opportunities; geographic commercialization via regional partnerships; ongoing preclinical studies, clinical development programs, and outsourced research services. Latest major company changes: enters strategic partnerships with pharmaceutical and academic collaborators to advance multiple candidates; completes Series B funding round to accelerate pipeline progression; acquires adjacent biotech assets to expand platform capabilities; launches new phase I/II clinical programs; reorients portfolio toward oncology and autoimmune indications; consolidates operations under a unified corporate structure; expands manufacturing footprint to support anticipated clinical-stage supply; appoints key executives to reinforce R&D and commercial enablement. These developments reflect recent alliances, financings, pipeline expansions, and organizational restructuring within the last 1–2 years. Additional context: industry focuses on biotechnology and pharmaceutical development; targets biopharma and research partners, contract development and manufacturing organizations (CDMOs), and academic collaborators; geographic presence spans North America, Europe, and Asia with subsidiaries and regional offices supporting global development and potential commercialization planning. Parent company relationships and subsidiary structures include strategic governance aligned to a centralized R&D and regulatory strategy.
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
BlossomHill Therapeutics (NASDAQ:BLSM) Director Bihua Chen Purchases 312,500 Shares of Stock
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
BlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline Promise